Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
Journal
The New England journal of medicine
Journal Volume
389
Journal Issue
21
Date Issued
2023-11-23
Author(s)
Planchard, David
Jänne, Pasi A
Cheng, Ying
Yanagitani, Noriko
Kim, Sang-We
Sugawara, Shunichi
Yu, Yan
Geater, Sarayut L
Laktionov, Konstantin
Lee, Chee K
Valdiviezo, Natalia
Ahmed, Samreen
Maurel, Jean-Marc
Andrasina, Igor
Goldman, Jonathan
Ghiorghiu, Dana
Rukazenkov, Yuri
Todd, Alex
Kobayashi, Kunihiko
Abstract
Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend the benefits of EGFR-TKI therapy.
SDGs
Type
journal article